Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Oxurion NV is a biopharmaceutical company headquartered in Leuven, Belgium, specializing in the development of next-generation therapies to preserve vision and prevent blindness in patients with retinal disorders. Founded in 1991 and formerly known as ThromboGenics NV until its rebranding in September 2018, the company targets conditions such as Geographic Atrophy and Age-related Macular Degeneration, the leading cause of vision loss among the elderly worldwide. Key pipeline candidates include THR-149, a plasma kallikrein inhibitor aimed at patients sub-optimally responding to anti-VEGF therapies, and THR-687, a pan-RGD integrin inhibitor designed as a potential standard of care for broader AMD populations. Oxurion employs innovative approaches like CRISPR-based target discovery to identify cytoprotective targets, addressing unmet needs in ophthalmology. With a lean team of about 11 employees, leadership includes CEO and CFO Pascal Ghoson, alongside executives like Andy De Deene and Philippe Barbeaux, and a board featuring Independent Chairman Charles Paris de Bollardiere. Recently, Oxurion has also pursued strategic acquisitions, such as a majority stake in Axiodis CRO, to build capabilities in biometrics and support healthcare stakeholders. In the financial markets, Oxurion NV represents a focused player in biotechnology, contributing to advancements in retinal disease treatments.
€0.00
€0.00 (-5.88%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-590.81% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 18400.0%, still solid. Margins contracted 13324.1pp, which offsets some of the top-line progress.
ROIC dropped from 3.15% to -22.75%, capital efficiency is deteriorating. Negative free cash flow of -€2M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€555K
▲ +18400.0% YoY
Net Income (TTM)
-€4M
▼ -3216.0% YoY
Op. Margin
-590.81%
▼ -13324.1pp YoY
ROIC
-22.75%
▼ -25.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€2M
▲ +17.6% YoY
Op. Cash Flow (TTM)
-€2M
▼ -4.5% YoY
Net Debt
€11M
Cash & Equiv.
€430K
3Y CAGR: -2.3%
Continue Research
Oxurion NV (OXUR.XBRU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Oxurion NV scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Oxurion NV scores 15 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -590.8% operating margin and a -22.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh OXUR.XBRU's valuation and scores 15/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.